- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
You are here
Eduardo Cazap, MD, PhD, FASCO
Founder, Latin American and Caribbean Society of Medical Oncology (SLACOM)
Past President, International Union again Cancer (UICC)
Buenos Aires, Argentina
Seeking to improve breast cancer treatments in women in Latin America
A clinical trial is ongoing to test two dosing regimens for a common anti-cancer drug to determine if a shorter course of treatment is as effective as the standard regimen.
This study can lead a sea change in the treatment of breast cancer in Latin America.
Breast cancer is the most common cancer in women in Latin America and is often diagnosed at a late stage. While advancements in treatment have been made in the last five years, five-year survival in Latin America hovers around 70 % and this is largely due to late diagnoses. Dr. Cazap is leading an international clinical trial in Argentina, Mexico and Peru to test an alternative chemotherapy dosing schedule to reduce toxic side effects of commonly used drug in women with metastatic breast cancer.
Full Research Summary
The SLACOM clinical trial is a multi-center, international Phase III trial led by Dr. Cazap and funded by BCRF. It is the first Latin American clinical trial solely supported by philanthropic funds (BCRF), without industry or government support. The purpose of the trial is to test the efficacy of an alternative dosing schedule for the oral anticancer drug, capecitabine, in patients with metastatic breast cancer.
The study investigators are testing whether a shorter dosing schedule of capecitabine (seven days of therapy followed by seven days of recovery) will have efficacy equal to the standard FDA-approved protocol (fourteen days of therapy followed by seven days of recovery).
The primary objectives of the study are to compare the safety and tolerability, response rate and rate of stable disease between the two dosing schedules following more than six months of treatment and to demonstrate that independent and privately funded research is possible in Latin America, which will greatly facilitate future studies and international collaborations.
The trial has enrolled 150 patients in five sites in Argentina, Mexico and Peru. In the coming year, the research team will conduct interim analysis of patient outcomes.
Eduardo Cazap MD, PhD received his medical degree in 1972 from the University of Buenos Aires and completed a residency in Internal Medicine at the Military Central Hospital and the Universidad del Salvador. He is a founder of the Latin American & Caribbean Society of Medical Oncology (SLACOM), Immediate Past- President of the International Union against Cancer (UICC), past Board Member of the American Society of Clinical Oncology (ASCO) and member of the Board of Directors of the National Cancer Institute of Argentina.
Dr. Cazap has published over 180 papers in global health, cancer control and prevention, breast cancer and independent clinical research. He has held many prominent positions, including Chairman of the Executive Committee of the Breast Health Global Initiative (BHGI) and Deputy Chair of the Emerging Countries Task Force and Co-Chair of the Global Task Force of the European Society of Medical Oncology (ESMO). He has been a member of the Developing Countries Task Force for ESMO since 2002. He is an active member of American Society of Clinical Oncology (ASCO) and was also recently elected to the ASCO Board of Directors representing the international members. Dr. Cazap also chairs the International Clinical Trials Working Group (ICTWG), a joint effort of ASCO and the National Cancer Institute, aimed at the improvement of independent clinical cancer research at the international level.
BCRF Investigator Since
The Blizzard Entertainment Award